Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RP438
- Development stage
- Preclinical
- Lead developer
- Riptide Bioscience
- Modality
- Peptides
- Administration
- Topical, Ophthalmic, Inhalation
01
Overview
RP438 is an engineered host defense peptide (dHDP) therapeutic developed by Riptide Bioscience. It is designed to mimic naturally occurring antimicrobial peptides with enhanced stability and activity. RP438 exhibits broad-spectrum bactericidal properties against Gram-positive and Gram-negative bacteria, including drug-resistant strains, by disrupting bacterial cell walls through electrostatic interactions. It is also effective against bacteria in biofilms. Currently in preclinical development, RP438 is being investigated for topical applications such as wound and burn recovery, keratitis, diabetic ulcers, and topical infections, as well as potential use in cystic fibrosis.
Beyond the preview
Go deeper on RP438.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RP438.